Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prv-001
- Development stage
- Preclinical
- Lead developer
- Odyssey Group International
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intranasal
01
Overview
PRV-001 is a first-in-class neurosteroid with anti-inflammatory and neuroprotective properties, originally developed by Odyssey Group International in joint venture with Prevacus for pediatric concussion and neurotrauma. Its mechanism of action is currently undefined, but it is categorized as a steroid and neuroprotectant. Further development has included acquisition by Oragenics in January 2024. PRV-001 has been investigated in preclinical settings for diseases like Niemann-Pick type C, with intranasal administration being the preferred route in pediatric applications[5].
- Brand names
- prv-001prv001prv 001onp-001onp001onp 001
- Other names
- prv-001prv001prv 001onp-001onp001onp 001
02
Targets
PXR (Pregnane X receptor)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on prv-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prv-001.